Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.86 |
| ▸ | MAP3K7 | O43318 | 7/20 | 0.86 |
| ▸ | IRAK1 | P51617 | 5/20 | 0.86 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29313973 | 0.93 | IRAK4 (0.74) | IRAK4MAP3K7IRAK1CHRM3EGFR | |
| SCHEMBL1924466 | 0.92 | MAP3K7 (1.00) | IRAK4MAP3K7IRAK1EGFRACKR3 | |
| SCHEMBL29313978 | 0.92 | MAP3K7 (0.73) | IRAK4MAP3K7IRAK1CHRM3EGFR | |
| SCHEMBL29313956 | 0.91 | IRAK4 (0.85) | IRAK4MAP3K7IRAK1EGFRACKR3 | |
| SCHEMBL21025639 | 0.91 | IRAK4 (0.71) | IRAK4MAP3K7IRAK1CHRM3EGFR | |
| SCHEMBL29313950 | 0.90 | IRAK4 (0.82) | IRAK4MAP3K7IRAK1EGFRACKR3 | |
| SCHEMBL21025910 | 0.88 | IRAK4 (0.67) | IRAK4MAP3K7IRAK1CHRM3EGFR | |
| SCHEMBL29313489 | 0.87 | IRAK4 (0.66) | IRAK4MAP3K7IRAK1CHRM3EGFR | |
| SCHEMBL1923717 | 0.86 | MAP3K7 (0.88) | IRAK4MAP3K7IRAK1CHRM3EGFR | |
| SCHEMBL20985396 | 0.86 | IRAK4 (0.76) | IRAK4MAP3K7IRAK1EGFRACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20220331297-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3710443-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885MAP3K7 536/4885IRAK1 1/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885MAP3K7 533/4885IRAK1 1/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885MAP3K7 536/4885IRAK1 1/4885 |
| US-20220331297-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885MAP3K7 536/4885IRAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.